Rezera, the company formerly known as NodThera, has filed for an IPO as it narrows its strategy around ruvonoflast, a brain-penetrant inhibitor of NOD-like receptor protein 3. The company has not said how many shares it plans to offer or at what price, but its Securities and Exchange Commission filing makes clear that ruvonoflast is the top priority for any proceeds.
The financing plan marks a sharper commercial turn than the company’s earlier positioning around obesity-related inflammation. Rezera now intends to use the IPO haul to move ruvonoflast through a planned phase 3 study next year in peripheral artery disease, or PAD, and to begin preparing for a potential commercial launch. With cash down to $3.9 million at the end of June, the filing also shows why public financing has become strategically important for the company rather than optional.
The lead program
Rezera selected PAD as its lead phase 3 indication in early September, around the time it rebranded. The company said the disease affects around 20 million adults in the U.S. and represents an estimated $5 billion market opportunity.
In the filing, Rezera said it chose PAD because it sees a significant unmet medical need in a large patient population with a high inflammatory burden and substantial morbidity despite broad use of lipid-lowering, antihypertensive and diabetes therapies. That rationale matters because it shifts the NLRP3 story from a biomarker-focused obesity setting toward a more direct cardiovascular market where a phase 3 program could support a launch thesis.
Earlier this month, the company reported phase 2 results for ruvonoflast in combination with Novo’s Wegovy ingredient semaglutide. In that study, the combination produced a statistically significant reduction in high-sensitivity C-reactive protein compared with semaglutide alone. But by the time those data were disclosed, Rezera had already decided PAD would be the path forward.
The company being built around it
The rebrand from NodThera last month was paired with a management overhaul. Geoff McDonough, a former CEO of Generation Bio, joined as CEO, and Jyothis George, a veteran of Amgen and Novo, joined as chief medical officer.
That combination of a public-markets financing attempt, a lead-indication reset and new leadership suggests Rezera is trying to present itself less as a platform biotech and more as a late-stage company built around one asset with a defined registration path. For investors, that can simplify the thesis, but it also concentrates execution risk on a single phase 3 strategy in PAD.
Rezera said some IPO proceeds would also support its earlier pipeline. The most advanced of those assets is trabzanoflast, another NLRP3 inhibitor optimized to enter the central nervous system. Trabzanoflast has completed phase 1 and is being developed for neuroinflammatory indications.
The company has 21 full-time employees across Boston and Cambridge, U.K. It has spent more than a decade working on NLRP3 inhibition, which it describes as targeting an upstream driver of sterile inflammation. The commercial question now is whether public investors will fund that science as a focused late-stage cardiovascular bet rather than a broader inflammation platform.
